The Zacks Analyst Blog Highlights: United States Brent Oil Fund, United States Oil Fund, PowerShares DB Oil Fund, iPath S&P GSCI Crude Oil Index ETN and Simcere Pharmaceutical Group

Zacks

 
For Immediate Release
Chicago, IL – August 30, 2013 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the United States Brent Oil Fund (BNO-Free Report), United States Oil Fund (USO-Free Report), PowerShares DB Oil Fund (DBO-Free Report), iPath S&P GSCI Crude Oil Index ETN (OIL-Free Report) and Simcere Pharmaceutical Group (SCR-Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations.
Get #1Stock of the Day pick for free.

Here are highlights from Thursday’s Analyst Blog:

Oil ETFs Jump on Syria Turmoil

Crude oil prices rebounded to the triple-digit mark at the start of the second half of the year after being stuck in a relatively tight range for much of the first half.
 
The commodity gained luster from encouraging economic data from the U.S., China and Euro zone as well as supply disruptions in the North Sea, Egypt and Libya (read: Oil ETFs Surge on Strong Data). Additionally, the commodity benefitted from the minutes of the latest Fed meeting, which suggested that QE3 tapering may not start soon.
 
Moreover, the ongoing tension in Syria has pushed the oil prices even higher this week. Brent oil hit a six month high and is currently hovering around $117 per barrel while crude oil reached its two-year high to about $112 per barrel.
 
Syria Threatens Oil Supply
 
The threat of military action in Syria could not only disrupt oil supplies in the rest of the Middle East including Nigeria, Libya and Sudan but raise alarms in the other oil exporting neighboring countries such as Iran and Iraq. Middle East accounts for about one-third of the world’s total
oil’s production.
 
As such, any supply disruptions in the region may lead to further rise in the oil prices. Moreover, rising global demand on the back of improving economies continues to act as a catalyst to the oil price surge (read: Bet on an Oil Surge with these 3 ETFs).
 
Market Impact
 
Growing concern over Syria outweighed the negative inventory data report from Energy Information Administration (EIA) for last week. According to the report, the U.S. crude stockpiles rose 3 million barrels to 362 million barrels last week (ending August 23) against the market expectation of a decline of 0.3 million barrels. 
 
The impressive jump in crude and Brent prices also had a big impact on oil ETFs this week, helping these to gains as well. Below, we have highlighted a few popular oil ETFs that could be interesting plays in the coming days, given the intensifying worries over Syria (see: all the energy ETFs here).
 
United States Brent Oil Fund (BNO-Free Report)
 
This fund provides direct exposure to the spot price of Brent crude oil on a daily basis through future contracts. It has amassed $39.7 million in its asset base and trades in small volume of roughly 35,000 shares a day.
 
The ETF charges 96 bps in annual fees and expenses. BNO added about 4.5% this week and 15.2% since the start of the second half.
 
United States Oil Fund (USO-Free Report)
 
This is the most popular and liquid ETF in the oil space with AUM of over $1.5 billion and average daily volume of over 5.7 million shares. The fund seeks to match the performance of the spot price of light sweet crude oil West Texas Intermediate (WTI). The ETF has 0.74% in expense ratio.
 
The ETF gained nearly 3% in the last three trading days and is up over 14% at the start of the second half (read: 3 Metal ETFs to Buy on the Commodity Upswing).
 
PowerShares DB Oil Fund (DBO-Free Report)
 
This product also provides exposure to crude oil through WTI futures contracts and follows the DBIQ Optimum Yield Crude Oil Index Excess Return. The fund sees solid average daily volume of more than 233,000 shares and AUM of $350 million. It charges an expense ratio of 79 bps.
 
DBO gained 1.4% so far this week and is up 8.7% in the first two months of the second half of the year.
 
iPath S&P GSCI Crude Oil Index ETN (OIL-Free Report)
 
This is an ETN option for oil investors and delivers returns through an unleveraged investment in the West Texas Intermediate (WTI) crude oil futures contract. The product follows the S&P GSCI Crude Oil Total Return Index, a subset of the S&P GSCI Commodity Index (read: 2 Commodity ETFs Offering Investors Sweet Returns).
 
The note has amassed $415 million in AUM so far and does volume of roughly 555,000 shares a day. It charges 75 bps in fees per year from investors. The ETN is up 3.4% this week and 16% since the start of the second half.
Bottom Line
 
Oil climbed nearly 27% from this year’s lows reached in mid April thanks to solid global data reports and dovish Fed comments. The more recent surge was propelled by political unrest in Egypt and the threat of U.S. intervention in Syria's civil war, suggesting that the trend could continue in the near future (see more in the Zacks ETF Center).
 
If it does, investors could consider any of the aforementioned oil ETFs for exposure. These could be solid ways to play the trend, and may be better performers compared to some of the sluggish oil companies for a continued run in crude oil prices in the near term.

Simcere to Go Private

Simcere Pharmaceutical Group (SCR-Free Report) recently announced that its Board has agreed to a buyout proposal from a conglomerate led by founder Mr. Jinsheng Ren, New Good Management Limited, Assure Ahead Investments Limited and its subsidiaries.

We remind investors that the proposal was initially made in Mar 2013. In response, Simcere’s Board formed a special committee of independent directors to consider the proposal.

Ren founded Simcere in Mar 1995. The conglomerate currently has an approximate 77.6% stake in Simcere.

As per the buyout offer, shareholders of Simcere will receive $4.83 per share or $9.66 per American depositary share (
ADS), up from the original offer of $4.78 per share or $9.56 per ADS. We note that each ADS represents two ordinary shares of Simcere. 

The offer price represents a 21.4% premium over the closing price of $7.96 per ADS on Mar 8, 2013.  The transaction is expected to close by 2013 end.

We note that Simcere’s decision to go private comes in the wake of tough business conditions that it has been facing in the last few months. 

Simcere’s second-quarter results were disappointing. Simcere is expected to face challenging market conditions in the remainder of 2013 as well due to pricing pressure from the government. 

Hence, the increased offer price should come as a relief to the shareholders.
Simcere Pharma currently carries a Zacks Rank #3 (Hold).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
 
 
About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
 
Get the full Report on BNO - FREE
Get the full Report on USO - FREE
Get the full Report on DBO - FREE
Get the full Report on OIL - FREE
Get the full Report on SCR - FREE
 
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
 
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
 
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Read the analyst report on BNO

Read the analyst report on USO

Read the analyst report on DBO

Read the analyst report on OIL

Read the analyst report on SCR

Zacks Investment Research



More From Zacks.com

Rates

View Comments (0)